Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Trial Details

NCT ID

NCT05417594

Phase

PHASE1 / PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

HER2 Negative Breast Cancer

Interventions

• AZD9574
• Temozolomide (TMZ)
• [11C]AZ1419 3391
• Trastuzumab Deruxtecan (T-DXd)
• Datopotamab Deruxtecan (Dato-DXd)

Locations (sample)

• La Jolla, California, United States|32.84727,-117.2742
• Los Angeles, California, United States|34.05223,-118.24368
• San Francisco, California, United States|37.77493,-122.41942
• Chicago, Illinois, United States|41.85003,-87.65005
• Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

• Eastern Cooperative Oncology Group performance status (ECOG PS) with no deterioration over the previous 2 weeks.
• Progressive cancer at the time of enrollment.
• Adequate organ and marrow function.
• \- Participants must have one of the following: (i) Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.